JP2005533038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533038A5 JP2005533038A5 JP2004509675A JP2004509675A JP2005533038A5 JP 2005533038 A5 JP2005533038 A5 JP 2005533038A5 JP 2004509675 A JP2004509675 A JP 2004509675A JP 2004509675 A JP2004509675 A JP 2004509675A JP 2005533038 A5 JP2005533038 A5 JP 2005533038A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- disorders
- carbon atoms
- treatment
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 claims description 16
- -1 trifluoroacetate salt compound Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000004432 carbon atom Chemical group C* 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 14
- 230000002265 prevention Effects 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 229910052801 chlorine Inorganic materials 0.000 claims 10
- 239000000460 chlorine Substances 0.000 claims 10
- 229910052794 bromium Inorganic materials 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 7
- 230000001154 acute effect Effects 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 208000020832 chronic kidney disease Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 208000030090 Acute Disease Diseases 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 206010041235 Snoring Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004946 alkenylalkyl group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 230000003871 intestinal function Effects 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 201000002859 sleep apnea Diseases 0.000 claims 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 208000007530 Essential hypertension Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 230000009692 acute damage Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000009693 chronic damage Effects 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 244000078703 ectoparasite Species 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000005989 gallbladder dysfunction Effects 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 244000144972 livestock Species 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 238000011477 surgical intervention Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 210000001835 viscera Anatomy 0.000 claims 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 1
- 125000006532 (C3-C5) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- HPDCPNVGZZXIOG-UHFFFAOYSA-N n-(2-bromo-4-methylthiophen-3-yl)-6-fluoro-1h-benzimidazol-2-amine Chemical compound CC1=CSC(Br)=C1NC1=NC2=CC(F)=CC=C2N1 HPDCPNVGZZXIOG-UHFFFAOYSA-N 0.000 claims 1
- OUJWXEIDCSOWLT-UHFFFAOYSA-N n-(2-chloro-4-methylthiophen-3-yl)-n-methyl-1h-benzimidazol-2-amine Chemical compound N=1C2=CC=CC=C2NC=1N(C)C=1C(C)=CSC=1Cl OUJWXEIDCSOWLT-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 0 CC(C(C)=N)=C(*)C(*)=C(C)N Chemical compound CC(C(C)=N)=C(*)C(*)=C(C)N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10224892A DE10224892A1 (de) | 2002-06-04 | 2002-06-04 | Substituierte Thiophene, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PCT/EP2003/005465 WO2003101984A1 (de) | 2002-06-04 | 2003-05-26 | Substituierte thiophene, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005533038A JP2005533038A (ja) | 2005-11-04 |
| JP2005533038A5 true JP2005533038A5 (enExample) | 2006-06-22 |
| JP4511924B2 JP4511924B2 (ja) | 2010-07-28 |
Family
ID=29557542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004509675A Expired - Fee Related JP4511924B2 (ja) | 2002-06-04 | 2003-05-26 | 置換チオフェン、その製造方法、医薬または診断薬としてのその使用、および、これを含有する医薬 |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1513834B1 (enExample) |
| JP (1) | JP4511924B2 (enExample) |
| KR (1) | KR101087966B1 (enExample) |
| CN (1) | CN1324024C (enExample) |
| AR (1) | AR040239A1 (enExample) |
| AT (1) | ATE320425T1 (enExample) |
| AU (1) | AU2003273553B2 (enExample) |
| BR (1) | BR0311548A (enExample) |
| CA (1) | CA2488242C (enExample) |
| CR (1) | CR7577A (enExample) |
| DE (2) | DE10224892A1 (enExample) |
| DK (1) | DK1513834T3 (enExample) |
| EC (1) | ECSP045471A (enExample) |
| ES (1) | ES2258722T3 (enExample) |
| HR (1) | HRP20041153A2 (enExample) |
| IL (1) | IL165519A (enExample) |
| MA (1) | MA27204A1 (enExample) |
| ME (1) | MEP27608A (enExample) |
| MX (1) | MXPA04011986A (enExample) |
| MY (1) | MY129832A (enExample) |
| NO (1) | NO329351B1 (enExample) |
| OA (1) | OA12827A (enExample) |
| PE (1) | PE20040534A1 (enExample) |
| PL (1) | PL372589A1 (enExample) |
| PT (1) | PT1513834E (enExample) |
| RS (1) | RS51141B (enExample) |
| RU (1) | RU2315766C2 (enExample) |
| TN (1) | TNSN04240A1 (enExample) |
| TW (1) | TWI283675B (enExample) |
| UA (1) | UA77551C2 (enExample) |
| WO (1) | WO2003101984A1 (enExample) |
| ZA (1) | ZA200409095B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242560A1 (en) | 2003-05-22 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Process for synthesizing heterocyclic compounds |
| DE10323701A1 (de) | 2003-05-22 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Verfahren zur Synthese heterocyclischer Verbindungen |
| IN2006CH00378A (en) | 2003-06-30 | 2007-05-11 | Sumitomo Chemical Co | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst |
| EP2088861A4 (en) * | 2006-10-25 | 2010-07-07 | Takeda Pharmaceutical | Benzimidazole compounds |
| AU2009289846B2 (en) | 2008-09-02 | 2014-10-16 | Sanofi-Aventis | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| RU2373929C1 (ru) * | 2008-11-11 | 2009-11-27 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) | Корректор системы гемостаза, проявляющий ингибирующее действие на адгезивно-агрегационную функцию тромбоцитов для профилактики патологического тромбообразования |
| RU2012120784A (ru) * | 2009-11-12 | 2013-12-20 | Селвита С.А. | Соединение, способ его получения, фармацевтическая композиция, применение соединения, способ модулирования или регулирования сериновых/треониновых киназ и средство, модулирующее сериновые/треониновые киназы |
| RU2518740C1 (ru) * | 2013-03-22 | 2014-06-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" | СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА |
| PL3173408T3 (pl) | 2014-07-25 | 2019-05-31 | Taisho Pharma Co Ltd | Związek fenylotetrahydroizochinolinowy podstawiony heteroarylem |
| KR102840252B1 (ko) * | 2023-04-27 | 2025-07-30 | 한국화학연구원 | 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| WO2025067474A1 (zh) * | 2023-09-28 | 2025-04-03 | 四川大学华西医院 | 一种含吡啶的化合物及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE754820R (fr) * | 1969-08-13 | 1971-02-15 | Schering Ag | Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs |
| BR6915362D0 (pt) * | 1969-08-16 | 1973-01-04 | Hoechst Ag | Processo para a preparacao de 2(tienil-3-amino)1,3-diazacicloalquenos |
| DE2830279A1 (de) * | 1978-07-10 | 1980-01-31 | Boehringer Sohn Ingelheim | 2-eckige klammer auf n-(2'-chlor-4'- methyl-thienyl-3')-n-(cyclopropylmethyl)- amino eckige klammer zu-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung |
| US5395847A (en) * | 1993-12-02 | 1995-03-07 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| DE19921883A1 (de) * | 1999-05-12 | 2000-11-16 | Bayer Ag | Substituierte Thienocycloalk(en)ylamino-1,3,5-triazine |
| DE19960204A1 (de) * | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| ATE447404T1 (de) * | 2002-03-29 | 2009-11-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
-
2002
- 2002-06-04 DE DE10224892A patent/DE10224892A1/de not_active Withdrawn
-
2003
- 2003-05-26 HR HR20041153A patent/HRP20041153A2/xx not_active Application Discontinuation
- 2003-05-26 ES ES03740148T patent/ES2258722T3/es not_active Expired - Lifetime
- 2003-05-26 AT AT03740148T patent/ATE320425T1/de active
- 2003-05-26 ME MEP-276/08A patent/MEP27608A/xx unknown
- 2003-05-26 WO PCT/EP2003/005465 patent/WO2003101984A1/de not_active Ceased
- 2003-05-26 CN CNB038128462A patent/CN1324024C/zh not_active Expired - Fee Related
- 2003-05-26 KR KR1020047019725A patent/KR101087966B1/ko not_active Expired - Fee Related
- 2003-05-26 UA UA20041211000A patent/UA77551C2/uk unknown
- 2003-05-26 RU RU2004138812/04A patent/RU2315766C2/ru not_active IP Right Cessation
- 2003-05-26 PL PL03372589A patent/PL372589A1/xx not_active Application Discontinuation
- 2003-05-26 RS YUP-1038/04A patent/RS51141B/sr unknown
- 2003-05-26 EP EP03740148A patent/EP1513834B1/de not_active Expired - Lifetime
- 2003-05-26 AU AU2003273553A patent/AU2003273553B2/en not_active Ceased
- 2003-05-26 OA OA1200400321A patent/OA12827A/en unknown
- 2003-05-26 PT PT03740148T patent/PT1513834E/pt unknown
- 2003-05-26 DK DK03740148T patent/DK1513834T3/da active
- 2003-05-26 BR BR0311548-8A patent/BR0311548A/pt not_active IP Right Cessation
- 2003-05-26 JP JP2004509675A patent/JP4511924B2/ja not_active Expired - Fee Related
- 2003-05-26 CA CA2488242A patent/CA2488242C/en not_active Expired - Fee Related
- 2003-05-26 MX MXPA04011986A patent/MXPA04011986A/es active IP Right Grant
- 2003-05-26 DE DE50302673T patent/DE50302673D1/de not_active Expired - Lifetime
- 2003-05-30 PE PE2003000531A patent/PE20040534A1/es not_active Application Discontinuation
- 2003-06-02 TW TW092114860A patent/TWI283675B/zh not_active IP Right Cessation
- 2003-06-02 AR ARP030101958A patent/AR040239A1/es active IP Right Grant
- 2003-06-03 MY MYPI20032052A patent/MY129832A/en unknown
-
2004
- 2004-11-10 ZA ZA200409095A patent/ZA200409095B/xx unknown
- 2004-11-16 MA MA27952A patent/MA27204A1/fr unknown
- 2004-11-19 CR CR7577A patent/CR7577A/es unknown
- 2004-12-02 IL IL165519A patent/IL165519A/en not_active IP Right Cessation
- 2004-12-02 EC EC2004005471A patent/ECSP045471A/es unknown
- 2004-12-03 TN TNP2004000240A patent/TNSN04240A1/en unknown
- 2004-12-16 NO NO20045504A patent/NO329351B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2326833C (en) | Indolyl-3-glyoxylic acid derivatives with antitumoral activity | |
| ES2243441T3 (es) | Derivados de imidazolio fundidos. | |
| JP2005505618A5 (enExample) | ||
| JP2005519932A5 (enExample) | ||
| JP2005533038A5 (enExample) | ||
| EP3315126A1 (en) | Conjugate of polyethylene glycol and anesthetic, and preparation method thereof | |
| JP2008510783A5 (enExample) | ||
| CA2410662A1 (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| JP2006515585A5 (enExample) | ||
| JP2004518723A5 (enExample) | ||
| CA2516370A1 (en) | A process of preparing imatinib and imatinib prepared thereby | |
| WO2001025190A1 (en) | Novel diarylamide derivatives and use thereof as medicines | |
| ES2437346T3 (es) | Procedimiento para la producción de derivado de diamina | |
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| CA2657550A1 (en) | Benzimidazole derivatives as selective acid pump inhibitors | |
| WO2020259602A1 (zh) | 苯二氮卓类化合物及其制备方法和在医药上的作用 | |
| JP2015502371A5 (enExample) | ||
| RU2004138812A (ru) | Замещенные тиофены, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащее их лекарственное средство | |
| RU2007124328A (ru) | Замещенные птеридины для лечения воспалительных заболеваний | |
| CN105616408B (zh) | 吡啶并[3,4-b]吲哚衍生物作为IDO抑制剂的用途 | |
| JP2004526721A5 (enExample) | ||
| SI1634595T1 (sl) | N-fenilbenzamidni derivati kot zdravila za zdravljenje kronične obstruktivne pljučne bolezni (KOPB) | |
| RU2005138143A (ru) | Митилиндолы и метилпирролопиридины в качестве l-1-адренергических агонистов | |
| CN108003218A (zh) | 柠檬苦素a环氨解衍生物、其制法以及医药用途 | |
| JP2006524677A5 (enExample) |